Federal Register / Vol. 74, No. 157 / Monday, August 17, 2009 / Notices 41449 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Immune Protection to 

Highly Lethal Pathogens by CD45 

Modulation. 

Date: September 9, 2009. 

Time: 12 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817 (Telephone Conference 

Call). 

Contact Person: Raymond Richard Schleef, 

PhD, Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institutes of Health/ 

NIAID, 6700B Rockledge Drive, MSC 7616, 

Bethesda, MD 20892–7616, 301–451–3679, 

schleefrr@niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 11, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–19687 Filed 8–14–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Advisory Dental and 

Craniofacial Research Council. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Dental and Craniofacial Research Council. 

Date: August 31, 2009. 

Time: 12 p.m. to 1 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Alicia J. Dombroski, PhD, 

Director, Division of Extramural Activities, 

Natl Inst of Dental and Craniofacial Research, 

National Institutes of Health, Bethesda, MD 

20892. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nidcr.nih.gov/about, where an agenda 

and any additional information for the 

meeting will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: August 11, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–19686 Filed 8–14–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2009–N–0664] 

Vaccines and Related Biological 

Products Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Vaccines and 

Related Biological Products Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on September 9, 2009, from 8 a.m. 

to approximately 5 p.m. 

Location: Hilton Hotel, Washington 

DC North/Gaithersburg, 620 Perry 

Pkwy., Gaithersburg, MD 20877. 

Contact Person: Christine Walsh or 

Denise Royster, Center for Biologics 

Evaluation and Research (HFM–71), 

Food and Drug Administration, 1401 

Rockville Pike, Rockville, MD 20852, 

301–827–0314, or FDA Advisory 

Committee Information Line, 1–800– 

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512391. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On September 9, 2009, in the 

morning, the committee will discuss 

and make recommendations on the 

safety and effectiveness in females of a 

vaccine manufactured by 

GlaxoSmithKline against Human 

Papillomavirus. In the afternoon, the 

committee will discuss and make 

recommendations on the safety and 

effectiveness of vaccinating males with 

Gardasil, a vaccine manufactured by 

Merck & Co. against Human 

Papillomavirus. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before September 4, 2009. 

Oral presentations from the public will 

be scheduled between approximately 

11:30 a.m. and 12 noon and between 

approximately 3:40 p.m. and 4:10 p.m. 

Those desiring to make formal oral 

presentations should notify the contact 

person and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation on or before August 

27, 2009. Time allotted for each 

presentation may be limited. If the 

number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by September 3, 2009. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

mstockstill on DSKH9S0YB1PROD with NOTICES

41450 Federal Register / Vol. 74, No. 157 / Monday, August 17, 2009 / Notices 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Christine 

Walsh or Denise Royster at least 7 days 

in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/Advisory

Committees/AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: August 11, 2009. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E9–19639 Filed 8–14–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of meetings of the National 

Heart, Lung, and Blood Advisory 

Council. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: September 1, 2009. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, C-Wing, Room 

10, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Stephen C. Mockrin, PhD, 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6701 

Rockledge Drive, Room 7100, Bethesda, MD 

20892, (301) 435–0260, 

mockrins@nhlbi.nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: September 15, 2009. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, A-Wing, Room 

5A05, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: Stephen C. Mockrin, PhD, 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6701 

Rockledge Drive, Room 7100, Bethesda, MD 

20892, (301) 435–0260, 

mockrins@nhlbi.nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

www.nhlbi.nih.gov/meetings/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research; 93.701, ARRA 

Related Biomedical Research and Research 

Support Awards, National Institutes of 

Health, HHS) 

Dated: August 10, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–19577 Filed 8–14–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention (CDC) 

Advisory Board on Radiation and 

Worker Health (ABRWH or Advisory 

Board), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention announces the 

following committee meeting: 

Time and Date: 11 a.m.–2 p.m., Tuesday, 

September 8, 2009. 

Place: Audio Conference Call via FTS 

Conferencing. The USA toll free dial in 

number is 1–866–659–0537 with a pass code 

of 9933701. 

Status: Open to the public, but without a 

public comment period. 

Background: The Advisory Board was 

established under the Energy Employees 

Occupational Illness Compensation Program 

Act of 2000 to advise the President on a 

variety of policy and technical functions 

required to implement and effectively 

manage the new compensation program. Key 

functions of the Advisory Board include 

providing advice on the development of 

probability of causation guidelines which 

have been promulgated by the Department of 

Health and Human Services (HHS) as a final 

rule, advice on methods of dose 

reconstruction which have also been 

promulgated by HHS as a final rule, advice 

on the scientific validity and quality of dose 

estimation and reconstruction efforts being 

performed for purposes of the compensation 

program, and advice on petitions to add 

classes of workers to the Special Exposure 

Cohort (SEC). 

In December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, which 

subsequently delegated this authority to the 

CDC. NIOSH implements this responsibility 

for CDC. The charter was issued on August 

3, 2001, renewed at appropriate intervals, 

will expire on August 3, 2011. 

Purpose: This Advisory Board is charged 

with (a) providing advice to the Secretary, 

HHS, on the development of guidelines 

under Executive Order 13179; (b) providing 

advice to the Secretary, HHS, on the 

scientific validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advising the Secretary on 

whether there is a class of employees at any 

Department of Energy facility who were 

exposed to radiation but for whom it is not 

feasible to estimate their radiation dose, and 

on whether there is reasonable likelihood 

that such radiation doses may have 

endangered the health of members of this 

class. 

Matters To Be Discussed: The agenda for 

the conference call includes: Blockson 

Chemical Company Radon Model Validation; 

Board Subcommittee and Work Group 

Updates; Board Working Groups Transcripts 

Reviews; OCAS SEC Petition Evaluations 

Update for October Board Meeting; DOL 

Consideration of OCAS Ruttenber Data 

Review. 

The agenda is subject to change as 

priorities dictate. 

Because there is not a public comment 

period, written comments may be submitted. 

Any written comments received will be 

included in the official record of the meeting 

and should be submitted to the contact 

person below in advance of the meeting. 

Contact Person for More Information: 

Theodore M. Katz, M.P.A., Executive 

Secretary, NIOSH, CDC, 1600 Clifton Rd. NE., 

Mailstop: E–20, Atlanta, GA 30333, 

Telephone (513) 533–6800, Toll Free 1–800– 

CDC–INFO, E-mail ocas@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both CDC and the Agency for Toxic 

Substances and Disease Registry. 

mstockstill on DSKH9S0YB1PROD with NOTICES